On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...